Fig. 2From: Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trialDistribution of the intrinsic subtypes before (a, c, e) and after treatment (b, d, f) in LTZ (a, b), mVNB-only (c, d), and combination (e and f) armsBack to article page